Alar Pharmaceuticals Overview
- Year Founded
-
2016
- Status
-
Public
- Employees
-
21
- Stock Symbol
-
6785
- Investments
-
2
- Share Price
-
$2.46
- (As of Thursday Closing)
Alar Pharmaceuticals General Information
Description
Alar Pharmaceuticals Inc is a drug development company mainly engaged in the research and development of new drugs, sales of western pharmaceuticals, and medical devices. It focuses on developing long-acting release drug products for CNS disorders and chronic diseases, which mainly include opioid use disorder, chronic pain, and depressive disorder. The company currently has only a new drug development division, and its product pipeline comprises various drug candidates such as ALA-1000 (Buprenorphine), ALA-1300, ALA-2000 (Naltrexone), ALA-3000 (Ketamine), ALA-4000 (Apomorphine), and ALA-5000 (Third-generation antipsychotic). Geographically, the company generates maximum revenue from the USA and also has its presence in Taiwan and the United Kingdom.
Contact Information
Website
www.alarpharm.comCorporate Office
- 5F., No.32, Keya Road
- Daya District
- Taichung
- Taiwan
Corporate Office
- 5F., No.32, Keya Road
- Daya District
- Taichung
- Taiwan
Alar Pharmaceuticals Stock Performance
As of 12-Nov-2026, Alar Pharmaceuticals’s stock price is $2.46. Its current market cap is $164M with 66.8M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.46 | $2.43 | $2.15 - $10.03 | $164M | 66.8M | 56.6K | -$0.03 |
Alar Pharmaceuticals Financials Summary
As of 30-Jun-2026, Alar Pharmaceuticals has a trailing 12-month revenue of $96.6K.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 171,853 | 574,675 | 213,728 | 360,257 |
| Revenue | 97 | 88 | 181 | 15,066 |
| EBITDA | (3,379) | (4,121) | (790) | 12,123 |
| Net Income | (2,322) | (2,554) | 566 | 12,284 |
| Total Assets | 76,790 | 79,542 | 77,732 | 31,672 |
| Total Debt | 58 | 114 | 18 | 46 |
Alar Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Alar Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Alar Pharmaceuticals Patents
Alar Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026092665-A1 | Apomorphine salts, their formulations and uses thereof | Pending | 31-Oct-2024 | ||
| AU-2026242204-A1 | Stable pharmaceutical composition of buprenorphine and preparation method and use thereo | Pending | 24-Jun-2022 | ||
| AU-2023287208-A1 | Stable pharmaceutical composition of buprenorphine and preparation method and use thereof | Inactive | 24-Jun-2022 | ||
| EP-4543448-A1 | Stable pharmaceutical composition of buprenorphine and preparation method and use thereof | Pending | 24-Jun-2022 | ||
| EP-4543448-A4 | Stable pharmaceutical composition of buprenorphine and preparation method and use thereof | Pending | 24-Jun-2022 | A61K31/485 |
Alar Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Alar Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Alar Pharmaceuticals Investments (2)
Alar Pharmaceuticals’s most recent deal was a Early Stage VC with Gilva Therapeutics for . The deal was made on 05-Mar-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Gilva Therapeutics | 05-Mar-2024 | Early Stage VC | Drug Discovery | ||
| Gilva Therapeutics | 01-Mar-2024 | Early Stage VC | Drug Discovery |
Alar Pharmaceuticals ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Alar Pharmaceuticals FAQs
-
When was Alar Pharmaceuticals founded?
Alar Pharmaceuticals was founded in 2016.
-
Where is Alar Pharmaceuticals headquartered?
Alar Pharmaceuticals is headquartered in Taichung, Taiwan.
-
What is the size of Alar Pharmaceuticals?
Alar Pharmaceuticals has 21 total employees.
-
What industry is Alar Pharmaceuticals in?
Alar Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Alar Pharmaceuticals a private or public company?
Alar Pharmaceuticals is a Public company.
-
What is Alar Pharmaceuticals’s stock symbol?
The ticker symbol for Alar Pharmaceuticals is 6785.
-
What is the current stock price of Alar Pharmaceuticals?
As of 12-Nov-2026 the stock price of Alar Pharmaceuticals is $2.46.
-
What is the current market cap of Alar Pharmaceuticals?
The current market capitalization of Alar Pharmaceuticals is $164M.
-
What is Alar Pharmaceuticals’s current revenue?
The trailing twelve month revenue for Alar Pharmaceuticals is $96.6K.
-
What is Alar Pharmaceuticals’s annual earnings per share (EPS)?
Alar Pharmaceuticals’s EPS for 12 months was -$0.03.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
